March 9, 2025 - 13:15

Readers hoping to buy C&F Financial Corporation for its dividend will need to make their move shortly, as the company approaches its upcoming ex-dividend date. Investors are keenly watching this stock, particularly those interested in income-generating investments. The timing of the ex-dividend date is crucial, as only those who purchase shares before this date will be eligible to receive the next dividend payment.
C&F Financial Corporation has established itself as a reliable player in the financial sector, and its dividend history reflects a commitment to returning value to shareholders. As the dividend yield remains attractive, potential investors are encouraged to conduct thorough research and consider their options before making a decision.
With market conditions fluctuating, the opportunity to invest in a company with a solid dividend track record may not last long. Investors should act quickly if they wish to take advantage of this potential income stream.
May 17, 2026 - 08:31
How Investors Are Reacting To NVE (NVEC) Steady Earnings And Maintained Quarterly DividendNVE Corporation has released its full-year results for the period ending March 31, 2026, posting revenue of US$26.33 million and net income of US$15.2 million. The company also confirmed a...
May 16, 2026 - 22:25
Risky Integration or Rewarding Returns? The Stakes of SoundHound's LivePerson Acquisition.SoundHound AI`s acquisition of LivePerson is drawing mixed reactions from investors, with the immediate fallout hitting the stock price. The deal, which combines SoundHound`s voice AI technology...
May 16, 2026 - 10:38
Bank of Hawaii, Glacier Bancorp, and Wintrust Financial Shares Plummet, What You Need To KnowShares of several regional banks took a sharp hit in afternoon trading Wednesday after the latest inflation report came in hotter than expected. The April Consumer Price Index rose 3.8%, a figure...
May 15, 2026 - 17:39
Plus Therapeutics Shares First Quarter 2026 Financial Results and Updates on REYOBIQ and CNSide ProgressHOUSTON, May 15, 2026 -- Plus Therapeutics, a healthcare company focused on precision diagnostics and radiopharmaceuticals for central nervous system cancers, reported its financial results for the...